# Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)

> **NCT03287232** · PHASE3 · COMPLETED · sponsor: **EndoCeutics Inc.** · enrollment: 653 (actual)

## Conditions studied

- Hypoactive Sexual Desire Disorder

## Interventions

- **DRUG:** Placebo Vaginal Insert
- **DRUG:** Prasterone 6.5 mg (0.50%) Vaginal Insert

## Key facts

- **NCT ID:** NCT03287232
- **Lead sponsor:** EndoCeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-16
- **Primary completion:** 2019-03-08
- **Final completion:** 2019-07-22
- **Target enrollment:** 653 (ACTUAL)
- **Last updated:** 2021-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03287232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03287232, "Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03287232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*